Epithelial ovarian cancer: Testing the 'androgens hypothesis'

Endocrine-Related Cancer

Volumn 15, Issue 4, 2008, Pages 1061-1068

  Olsen, Catherine M ^a,b   Green, Adèle C ^a   Nagle, Christina M ^a   Jordan, Susan J ^a,b   Whiteman, David C ^a   Bain, Christopher J ^b   Webb, Penelope M ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DANAZOL; TESTOSTERONE;

ACNE; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; CANCER REGISTRY; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIRSUTISM; HORMONE DETERMINATION; HUMAN; HYPERANDROGENISM; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY POLYCYSTIC DISEASE; PATIENT SELECTION; POPULATION BASED CASE CONTROL STUDY; SELF REPORT;

ACNE VULGARIS; ADOLESCENT; ADULT; AGED; AUSTRALIA; BODY MASS INDEX; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; DANAZOL; ESTROGEN ANTAGONISTS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HIRSUTISM; HUMANS; HYPERANDROGENISM; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OBESITY; OVARIAN NEOPLASMS; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; WEIGHT GAIN; YOUNG ADULT;

EID: 58249116740     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-08-0075     Document Type: Article

References (45)

1. ABS 2006 2004-05 National Health Survey: summary of results, vol. Cat. No. 4364, pp 92. Australian Bureau of Statistics.
2. Azziz R 2003 Androgen excess is the key element in polycystic ovary syndrome. Fertility and Sterility 80 252-254.
3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES & Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology and Metabolism 89 2745-2749.
4. Bell DA 2005 Origins and molecular pathology of ovarian cancer. Modern Pathology 18 (Supplement 2) S19-S32.
5. Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C & Castagna G 1998 Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. Journal of Experimental & Clinical Cancer Research 17 231-237.
6. Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC & van der Kwast TH 1993 An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Human Pathology 24 90-95.
7. Cottreau CM, Ness RB, Modugno F, Allen GO & Goodman MT 2003 Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer. Clinical Cancer Research 9 5142-5144.
8. Coulam CB, Annegers JF & Kranz JS 1983 Chronic anovulation syndrome and associated neoplasia. Obstetrics and Gynecology 61 403-407.
9. Dizon DS, Tejada-Berges T, Koelliker S, Steinhoff M & Granai CO 2006 Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecologic and Obstetric Investigation 62 226-228.
10. Edmondson RJ, Monaghan JM & Davies BR 2002 The human ovarian surface epithelium is an androgen responsive tissue. British Journal of Cancer 86 879-885.
11. Gambineri A, Pelusi C, Vicennati V, Pagotto U & Pasquali R 2002 Obesity and the polycystic ovary syndrome. International Journal of Obesity and Related Metabolic Disorders 26 883-896.
12. Gaspard UJ, Romus MA, Gillain D, Duvivier J, Demey-Ponsart E & Franchimont P 1983 Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception 27 577-590.
13. Greer JB, Modugno F, Allen GO & Ness RB 2005 Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstetrics and Gynecology 105 731-740.
14. Hage JJ, Dekker JJ, Karim RB, Verheijen RH & Bloemena E 2000 Ovarian cancer in female-to-male transsexuals: report of two cases. Gynecologic Oncology 76 413-415.
15. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC & Comstock GW 1995 Serum gonadotropins and steroid hormones and the development of ovarian cancer. Journal of the American Medical Association 274 1926-1930.
16. Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C & Scoccia B 1997 Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecologic Oncology 66 250-254.
17. Jordan SJ, Green AC, Whiteman DC & Webb PM 2007 Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecologic Oncology 107 223-230.
18. Kuhnel R, de Graaff J, Rao BR & Stolk JG 1987 Androgen receptor predominance in human ovarian carcinoma. Journal of Steroid Biochemistry 26 393-397.
19. Lau KM, Mok SC & Ho SM 1999 Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. PNAS 96 5722-5727.
20. Lucky AW 1995 Hormonal correlates of acne and hirsutism. American Journal of Medicine 98 89S-94S.
21. Lukanova A & Kaaks R 2005 Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiology, Biomarkers and Prevention 14 98-107.
22. Lukanova A, Lundin E, Akhmedkhanov A, Micheli A, Rinaldi S, Zeleniuch-Jacquotte A, Lenner P, Muti P, Biessy C, Krogh V et al. 2003 Circulating levels of sex steroid hormones and risk of ovarian cancer. International Journal of Cancer 104 636-642.
23. Merritt MA, Green AC, Nagle CM & Webb PM 2008 Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. International Journal of Cancer 122 170-176.
24. Modugno F 2004 Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: a HuGE review. American Journal of Epidemiology 159 319-335.
25. Murphy A, Cropp CS, Smith BS, Burkman RT & Zacur HA 1990 Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women. Fertility and Sterility 53 35-39.
26. Olive DL & Pritts EA 2001 Treatment of endometriosis. New England Journal of Medicine 345 266-275.
27. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH & Jacobs HS 1998 Mortality of women with polycystic ovary syndrome at long-term follow-up. Journal of Clinical Epidemiology 51 581-586.
28. Polson DW, Adams J, Wadsworth J & Franks S 1988 Polycystic ovaries - a common finding in normal women. Lancet 1 870-872.
29. Purdie DM, Webb PM, Siskind V, Bain CJ & Green AC 2003 The different etiologies of mucinous and nonmucinous epithelial ovarian cancers. Gynecologic Oncology 88 S145-S148.
30. Rinaldi S, Dossus L, Lukanova A, Peeters PH, Allen NE, Key T, Bingham S, Khaw KT, Trichopoulos D, Trichopoulou A et al. 2007 Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiology, Biomarkers and Prevention 16 23-29.
31. Risch HA 1998 Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. Journal of the National Cancer Institute 90 1774-1786.
32. Risch HA, Marrett LD, Jain M & Howe GR 1996 Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. American Journal of Epidemiology 144 363-372.
33. Sawada M, Terada N, Wada A, Mori Y, Yamasaki M, Saga T & Endo K 1990 Estrogen- and androgen-responsive growth of human ovarian adenocarcinoma hetefotransplanted into nude mice. International Journal of Cancer 45 359-363.
34. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A & Hughes C 1996 Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstetrics and Gynecology 88 554-559.
35. Shih Ie M & Kurman RJ 2004 Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. American Journal of Pathology 164 1511-1518.
36. Silva EG, Tornos C, Fritsche HA Jr, el-Naggar A, Gray K, Ordonez NG, Luna M & Gershenson D 1997 The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Modern Pathology 10 879-883.
37. Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, Kurman RJ & Shih Ie M 2003 Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Journal of the National Cancer Institute 95 484-486.
38. Slotman BJ & Rao BR 1989 Response to inhibition of androgen action of human ovarian cancer cells in vitro. Cancer Letters 45 213-220.
39. Solomon CG 1999 The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinology and Metabolism Clinics of North America 28 247-263.
40. Stewart SL, Querec TD, Gruver BN, O'Hare B, Babb JS & Patriotis C 2004 Gonadotropin and steroid hormones stimulate proliferation of the rat ovarian surface epithelium. Journal of Cellular Physiology 198 119-124.
41. Syed V, Ulinski G, Mok SC, Yin GK & Ho SM 2001 Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Research 61 6768-6776.
42. Tennent BJ, Shultz KL & Beamer WG 1993 Genetic susceptibility for C19 androgen induction of ovarian granulosa cell tumorigenesis in SWXJ strains of mice. Cancer Research 53 1059-1063.
43. Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA & Greenberg ER 2001 Menstrual and reproductive factors in relation to ovarian cancer risk. British Journal of Cancer 84 714-721.
44. Tworoger SS, Lee IM, Buring JE & Hankinson SE 2007 Plasma androgen concentrations and risk of incident ovarian cancer. American Journal of Epidemiology 167 211-218.
45. Wynder EL, Dodo H & Barber HR 1969 Epidemiology of cancer of the ovary. Cancer 23 352-370.